Biotech leader eyes spin-off amid massive sales surge
Biotech stock Anaptysbio cleared a trendline entry near 50 on Monday. Shares are also in a base with a buy point of 52.47.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments